Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank
Journal of Cancer Research and Clinical Oncology · 2024-08-24 · 150 (8)
DOI: 10.1007/s00432-024-05919-8 ↗At a glance
Kohortenstudie in Journal of Cancer Research and Clinical Oncology, published online on 2024-08-24. Written by Chuang Yang and 5 co-authors. Institution: Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Liebigstr. 20, D-04103, Leipzig, Germany. Major MEDLINE topics: Esophageal Neoplasms, Insulin Resistance, Biological Specimen Banks. Cited 19 times so far (Crossref); 45 references. The full text is freely available (open access, CC BY 4.0). Funded by: Universitätsklinikum Leipzig.
Abstract (original language)
Purpose
This study explored the association between triglyceride-glucose (TyG), TyG index with body mass index (TyG-BMI), triglyceride/high-density lipoprotein cholesterol ratio (TG/HDL-C), metabolic score for insulin resistance (IR) (METS-IR) and the risk of esophageal cancer.
Methods
A total of 388,900 participants from the United Kingdom Biobank from 2006 to 2010 were included. Fine-Gray models, restricted cubic spline (RCS), and receiver operating characteristic (ROC) curves were used to assess the association between the four IR surrogates and the risk of esophageal cancer, specifically, esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC).
Results
Ten years after recruitment, 0.16% (95%CI 0.11–0.26%) had esophageal cancer and 4.17% (95%CI 3.86–4.46%) are deceased. For each standard deviation increase in the TyG index, TyG-BMI, TG/HDL-C, and METS-IR, the risk of EAC increased by Hazard ratios (HR)1.16, 1.37, 1.08, and 1.36, respectively (all P < 0.05), while the risk of ESCC decreased by HRs 0.80, 0.67, 0.77, and 0.65, respectively. RCS analysis indicated that most relationships were nonlinear ( P < 0.05). ROC curves showed that METS-IR had a more robust diagnostic efficacy than TyG, TyG-BMI, and TG/HDL-C.
Conclusion
TyG index, TyG-BMI, TG/HDL-C, and METS-IR were closely associated with the risk of EAC and ESCC. Additionally, METS-IR surpassed the other three IR indices in predicting and diagnosing the risks of EAC and ESCC. The METS-IR is expected to become a more effective metric for identifying populations at early risk of esophageal cancer and for improving risk stratification.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Liebigstr. 20, D-04103, Leipzig, Germany.
- Medical Faculty, University of Leipzig, Leipzig, Germany.
- Institute of Biostatistics and Clinical Research, University of Muenster, Muenster, Germany.
- Department of Visceral, Transplant, Thoracic and Vascular Surgery, University Hospital Leipzig, Liebigstr. 20, D-04103, Leipzig, Germany. rene.thieme@medizin.uni-leipzig.de.
Funding
- Universitätsklinikum Leipzig
Cite
APA
Yang, C., Cheng, W., Plum, P. S., Köppe, J., Gockel, I., & Thieme, R. (2024). Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank. Journal of Cancer Research and Clinical Oncology, 150(8). https://doi.org/10.1007/s00432-024-05919-8
Vancouver
Yang C, Cheng W, Plum PS, Köppe J, Gockel I, Thieme R. Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank. Journal of Cancer Research and Clinical Oncology. 2024;150(8). doi:10.1007/s00432-024-05919-8
BibTeX
@article{Yang2024,
author = {Yang, Chuang and Cheng, Wenke and Plum, Patrick S and Köppe, Jeanette and Gockel, Ines and Thieme, René},
title = {Association between four insulin resistance surrogates and the risk of esophageal cancer: a prospective cohort study using the UK Biobank},
journal = {Journal of Cancer Research and Clinical Oncology},
year = {2024},
volume = {150},
number = {8},
doi = {10.1007/s00432-024-05919-8}
}
EUVIMED